Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer
NCT00040170 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2006-11-02
Summary
This study involves the use of an experimental product, TG4010. The purpose of the study is to determine if TG4010 can stimulate the body's immune system to help it fight the cancer.
Conditions
- Prostatic Neoplasms
Interventions
- BIOLOGICAL
-
MVA-MUC1-IL2
Sponsors & Collaborators
-
University of California, Los Angeles
collaborator OTHER -
The Cleveland Clinic
collaborator OTHER -
University of Arizona
collaborator OTHER -
Transgene
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-05-31
Countries
- United States
Study Locations
More Related Trials
-
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
NCT00004029 ·Status: COMPLETED ·Phase: PHASE1
-
Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate Cancer
NCT00579423 ·Status: COMPLETED ·Phase: PHASE2
-
Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer
NCT00616291 ·Status: COMPLETED ·Phase: PHASE1
-
Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer
NCT00036933 ·Status: COMPLETED ·Phase: PHASE1
-
Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer
NCT00514072 ·Status: UNKNOWN ·Phase: PHASE2
-
Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer
NCT00017537 ·Status: WITHDRAWN ·Phase: PHASE1
-
Vaccine Therapy in Treating Patients With Non-Metastatic Prostate Cancer
NCT00814892 ·Status: TERMINATED ·Phase: PHASE2
-
Tumor Cell Vaccine in Treating Patients With Advanced Cancer
NCT00002505 ·Status: COMPLETED ·Phase: PHASE2
-
Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer
NCT00030602 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)
NCT02179515 ·Status: COMPLETED ·Phase: PHASE1
-
PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer
NCT00005916 ·Status: COMPLETED ·Phase: PHASE2
-
Mouse Cancer Cell-containing Macrobeads in the Treatment of Human Cancer
NCT00283075 ·Status: COMPLETED ·Phase: PHASE1
-
A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence
NCT04298606 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
NCT00032045 ·Status: COMPLETED ·Phase: PHASE2
-
Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer
NCT00640861 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma
NCT01569919 ·Status: UNKNOWN ·Phase: PHASE2
-
MUC1 Vaccine for Triple-negative Breast Cancer
NCT00986609 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer
NCT00706615 ·Status: WITHDRAWN ·Phase: PHASE1
-
Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2
NCT00031564 ·Status: COMPLETED ·Phase: PHASE2
-
Novel Peptide Vaccination for Patients With Advanced Prostate Cancer
NCT01225471 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
NCT03836157 ·Status: WITHDRAWN ·Phase: PHASE2
-
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
NCT05098210 ·Status: RECRUITING ·Phase: PHASE1
-
Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00015977 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma
NCT00061035 ·Status: COMPLETED ·Phase: PHASE1
-
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
NCT00085189 ·Status: COMPLETED ·Phase: PHASE2